Profile
Francesco Balestrieri served as Chief Executive Officer at Sandoz International GmbH in 2019 and as Director at Sandoz Ltd.
from 2018 to 2019.
He holds a Master's degree in Business Administration from Universita Ca' Foscari di Venezia.
Former positions of Francesco Balestrieri
| Companies | Position | End |
|---|---|---|
Sandoz International GmbH
 Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Chief Executive Officer | 2019-07-31 |
Sandoz Ltd.
 Sandoz Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Ltd. is a British company that develops, produces and markets medicines. The company is based in Camberley, UK and was founded in 1981. | Director/Board Member | 2019-07-21 |
Training of Francesco Balestrieri
| Universita Ca' Foscari di Venezia | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Sandoz Ltd.
Sandoz Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Ltd. is a British company that develops, produces and markets medicines. The company is based in Camberley, UK and was founded in 1981. | Health Technology |
Sandoz International GmbH
Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Health Technology |
- Stock Market
- Insiders
- Francesco Balestrieri
